Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation
Jörg Ruof (),
J.-Matthias Schulenburg and
The European Journal of Health Economics, 2014, vol. 15, issue 6, 577-589
Considerable variance was observed in the levels of additional benefit reported by pharmaceutical manufacturers, IQWiG and G-BA. The areas of disagreement included ACT selection, definition of subgroups and patient-relevant endpoints, and classification and balancing of adverse events. Copyright The Author(s) 2014
Keywords: Health care reform; (Early) benefit assessment; Appropriate comparative therapy; Market access; AMNOG; I10; I11; I18 (search for similar items in EconPapers)
References: View complete reference list from CitEc
Citations: View citations in EconPapers (7) Track citations by RSS feed
Downloads: (external link)
Access to full text is restricted to subscribers.
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:15:y:2014:i:6:p:577-589
Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2
Access Statistics for this article
The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg
More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla ().